BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22551903)

  • 1. Thymidylate synthase protein expression by IHC and gene copy number by SISH correlate and show great variability in non-small cell lung cancer.
    Wynes MW; Konopa K; Singh S; Reyna-Asuncion B; Ranger-Moore J; Sternau A; Christoph DC; Dziadziuszko R; Jassem J; Hirsch FR
    J Thorac Oncol; 2012 Jun; 7(6):982-92. PubMed ID: 22551903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thymidylate synthase expression and outcome of patients receiving pemetrexed for advanced nonsquamous non-small-cell lung cancer in a prospective blinded assessment phase II clinical trial.
    Nicolson MC; Fennell DA; Ferry D; O'Byrne K; Shah R; Potter V; Skailes G; Upadhyay S; Taylor P; André V; Nguyen TS; Myrand SP; Visseren-Grul C; Das M; Kerr KM
    J Thorac Oncol; 2013 Jul; 8(7):930-9. PubMed ID: 23722170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project.
    Bubendorf L; Dafni U; Schöbel M; Finn SP; Tischler V; Sejda A; Marchetti A; Thunnissen E; Verbeken EK; Warth A; Sansano I; Cheney R; Speel EJM; Nonaka D; Monkhorst K; Hager H; Martorell M; Savic S; Kerr KM; Tan Q; Tsourti Z; Geiger TR; Kammler R; Schulze K; Das-Gupta A; Shames D; Peters S; Stahel RA;
    Lung Cancer; 2017 Sep; 111():143-149. PubMed ID: 28838386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thymidylate synthase gene amplification predicts pemetrexed resistance in patients with advanced non-small cell lung cancer.
    Shimizu T; Nakagawa Y; Takahashi N; Hashimoto S
    Clin Transl Oncol; 2016 Jan; 18(1):107-12. PubMed ID: 26220094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF; Rojas L; Wills B; Arrieta O; Carranza H; Vargas C; Otero J; Cuello M; Corrales L; Martín C; Ortiz C; Franco S; Rosell R;
    PLoS One; 2016; 11(5):e0154293. PubMed ID: 27191954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction.
    Shintani Y; Ohta M; Hirabayashi H; Tanaka H; Iuchi K; Nakagawa K; Maeda H; Kido T; Miyoshi S; Matsuda H
    Int J Cancer; 2003 May; 104(6):790-5. PubMed ID: 12640689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of the polymorphisms in thymidylate synthase and methylenetetrahydrofolate reductase gene in lung cancer.
    Takehara A; Kawakami K; Ohta N; Oyama K; Ota Y; Oda M; Watanabe G
    Anticancer Res; 2005; 25(6C):4455-61. PubMed ID: 16334126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase and dihydrofolate reductase expression in non-small cell lung carcinoma: the association with treatment efficacy of pemetrexed.
    Chen CY; Chang YL; Shih JY; Lin JW; Chen KY; Yang CH; Yu CJ; Yang PC
    Lung Cancer; 2011 Oct; 74(1):132-8. PubMed ID: 21367480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis.
    Wang L; Wang R; Pan Y; Sun Y; Zhang J; Chen H
    BMC Cancer; 2014 Mar; 14():205. PubMed ID: 24641970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effectiveness of Pemetrexed Monotherapy Depending on Polymorphisms in TS and MTHFR Genes as Well as Clinical Factors in Advanced NSCLC Patients.
    Kucharczyk T; Krawczyk P; Powrózek T; Kowalski DM; Ramlau R; Kalinka-Warzocha E; Knetki-Wróblewska M; Winiarczyk K; Krzakowski M; Milanowski J
    Pathol Oncol Res; 2016 Jan; 22(1):49-56. PubMed ID: 26277606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of thymidylate synthase gene 3'-untranslated region polymorphism with sensitivity of non-small cell lung cancer to pemetrexed treatment: TS gene polymorphism and pemetrexed sensitivity in NSCLC.
    Wang X; Wang Y; Wang Y; Cheng J; Wang Y; Ha M
    J Biomed Sci; 2013 Jan; 20(1):5. PubMed ID: 23350714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase gene copy number as a predictive marker for response to pemetrexed treatment of lung adenocarcinoma.
    Kasai D; Ozasa H; Oguri T; Miyazaki M; Uemura T; Takakuwa O; Kunii E; Ohkubo H; Maeno K; Niimi A
    Anticancer Res; 2013 May; 33(5):1935-40. PubMed ID: 23645741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes.
    Ibe T; Shimizu K; Nakano T; Kakegawa S; Kamiyoshihara M; Nakajima T; Kaira K; Takeyoshi I
    J Surg Oncol; 2010 Jul; 102(1):11-7. PubMed ID: 20578072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
    Takezawa K; Okamoto I; Okamoto W; Takeda M; Sakai K; Tsukioka S; Kuwata K; Yamaguchi H; Nishio K; Nakagawa K
    Br J Cancer; 2011 May; 104(10):1594-601. PubMed ID: 21487406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of thymidylate synthase in non-small cell lung cancer treated with pemetrexed continuation maintenance therapy.
    Yang M; Fan WF; Pu XL; Meng LJ; Wang J
    J Chemother; 2017 Apr; 29(2):106-112. PubMed ID: 27866454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC and human telomerase gene (TERC) copy number gain in early-stage non-small cell lung cancer.
    Flacco A; Ludovini V; Bianconi F; Ragusa M; Bellezza G; Tofanetti FR; Pistola L; Siggillino A; Vannucci J; Cagini L; Sidoni A; Puma F; Varella-Garcia M; Crinò L
    Am J Clin Oncol; 2015 Apr; 38(2):152-8. PubMed ID: 25806711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung.
    Hashimoto H; Ozeki Y; Sato M; Obara K; Matsutani N; Nakagishi Y; Ogata T; Maehara T
    Cancer; 2006 Apr; 106(7):1595-601. PubMed ID: 16489621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.
    Niedzwiecki D; Hasson RM; Lenz HJ; Ye C; Redston M; Ogino S; Fuchs CS; Compton CC; Mayer RJ; Goldberg RM; Colacchio TA; Saltz LB; Warren RS; Bertagnolli MM
    Oncologist; 2017 Jan; 22(1):107-114. PubMed ID: 27821793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of folate receptor alpha and thymidylate synthase protein expression in patients with non-small-cell lung cancer treated with pemetrexed.
    Christoph DC; Asuncion BR; Hassan B; Tran C; Maltzman JD; O'Shannessy DJ; Wynes MW; Gauler TC; Wohlschlaeger J; Hoiczyk M; Schuler M; Eberhardt WE; Hirsch FR
    J Thorac Oncol; 2013 Jan; 8(1):19-30. PubMed ID: 23242435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.